Handel nachbörslich: .30 -0.008 -2.60%

Cara Therapeutics Inc (CARA)

Cara Therapeutics Inc Aktie (CARA) Neueste Nachrichten

Cara Therapeutics Inc (CARA)

Cara Therapeutics Inc Aktie (CARA) Neueste Nachrichten

Market Recap: Cara Therapeutics Inc (CARA)’s Positive Momentum, Closing at 0.31 - The Dwinnex

Stock Analysts’ New Coverage for September 26th (AINC, AIRI, APTO, BLK, CARA, CBOE, CLLS, CME, CMLS, CTLT) - Defense World

Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com - Defense World

Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace

A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News

Pruritus Clinical Trials 2024: FDA Approvals, Medication, - openPR

Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada

Aclaris Therapeutics neutral rating reiterated on phase 2a trial - Investing.com

Federated Hermes Inc. Acquires Shares of 670,468 Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Carmat launches capital increase, stock plummets - Marketscreener.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire

What technical indicators reveal about CARA stock - US Post News

The time has not yet come to remove your chips from the table: Cara Therapeutics Inc (CARA) - SETE News

Cara Therapeutics Inc (CARA)’s Day in Review: Closing at 0.26, Down by -2.85 - The Dwinnex

CARA’s Stock Market Adventure: -62.18% YTD Growth Amidst Volatility - The InvestChronicle

How to interpret Cara Therapeutics Inc (CARA)’s stock chart patterns - US Post News

Pruritus Therapeutics Market Competition & Segment Analysis – Actavis Plc, Amgen Inc., Bristol-Myers Squibb, Cara Therapeutics, Cipla – Cauverynews - Cauverynews

Metric Deep Dive: Understanding Cara Therapeutics Inc (CARA) Through its Ratios - The Dwinnex

Pruritus Pipeline Analysis 2024: FDA Approvals and Emerging - openPR

Does Cara Therapeutics Inc (CARA) offer a good opportunity for investors? - SETE News

Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com - Defense World

Following more layoffs, Stamford’s Cara Therapeutics considers ‘strategic alternatives,’ including dissolving company - Hartford Business Journal

Analysts review Cara Therapeutics Inc’s rating - Knox Daily

Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Rating of “Hold” by Brokerages - Defense World

Vanguard Group Inc. Reduces Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World

CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace

Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World

Cara Therapeutics (NASDAQ:CARA) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS - Defense World

Cara: Q2 Earnings Snapshot - San Antonio Express-News

Cara: Q2 Earnings Snapshot - The Washington Post

Cara: Q2 Earnings Snapshot - Milton Daily Standard

Cara: Q2 Earnings Snapshot - Thehour.com

Investing in Cara Therapeutics Inc (CARA) Is Getting More Attractive - Knox Daily

Understanding the Risks of Investing in Gain Therapeutics Inc (GANX) - Knox Daily

Cara Therapeutics receives Nasdaq compliance extension - Investing.com India

Cara Therapeutics CEO sells over $1,400 in stock - Investing.com India

Cara Therapeutics receives Nasdaq compliance extension By Investing.com - Investing.com Australia

Cara Therapeutics CEO sells over $1,400 in stock - Investing.com

Cara Therapeutics receives Nasdaq compliance extension - Investing.com

Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Taking the lead: Cara Therapeutics Inc (CARA) - SETE News

Cara Therapeutics Inc (CARA) deserves deeper analysis - US Post News

CT-based bioscience firm Cara Therapeutics eliminates most of workforce, filing indicates - CT Insider

5 Biotechs That May Surge On Takeovers - Investopedia

Medical Marijuana Market Growth Drivers | Cannabis Sativa, Inc.; Cara Therapeutics Inc., Inc.; United Cannabis Corporation – Economica - Economica

Cara Therapeutics (NASDAQ:CARA) Share Price Passes Below 200 Day Moving Average of $0.65 - Defense World

Recent Insider Activity Could Benefit Cara Therapeutics Inc (CARA) - Knox Daily

Cara Therapeutics (NASDAQ:CARA) Research Coverage Started at StockNews.com - Defense World

These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers' - MSN

Sarcoma Therapeutics Market Is Booming Worldwide | Agenus, Agios, Eisai - openPR

Insider Selling: Posner Christopher, Cara Therapeutics Inc [CARA] PRESIDENT AND CEO divested 3,936 shares - Knox Daily

Riding the Waves: A Guide to Investing in CARA Stock - The InvestChronicle

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34% - Simply Wall St

Cara Therapeutics Inc (CARA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

How does Cara Therapeutics Inc (CARA) change from a tortoise to a hare? - SETE News

Investing in Cara Therapeutics Inc (CARA) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News

Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com - Defense World

Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com - American Banking and Market News

CARA (Cara Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily

Ähnlich wie CARA